Symbols / ALLR
ALLR Chart
About
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 15.28M |
| Enterprise Value | -483.71K | Income | -15.31M | Sales | — |
| Book/sh | 0.74 | Cash/sh | 1.07 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | 0.10 | Forward P/E | -0.98 | PEG | — |
| P/S | — | P/B | 1.28 | P/C | — |
| EV/EBITDA | 0.03 | EV/Sales | — | Quick Ratio | 2.11 |
| Current Ratio | 2.33 | Debt/Eq | 11.57 | LT Debt/Eq | — |
| EPS (ttm) | 9.11 | EPS next Y | -0.97 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 09:00 | ROA | -51.62% |
| ROE | -122.61% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 16.08M |
| Shs Float | 15.79M | Short Float | 1.34% | Short Ratio | 1.69 |
| Short Interest | — | 52W High | 2.35 | 52W Low | 0.61 |
| Beta | 0.23 | Avg Volume | 164.48K | Volume | 88.05K |
| Target Price | $9.50 | Recom | None | Prev Close | $0.94 |
| Price | $0.95 | Change | 0.82% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.50
Mean price target
2. Current target
$0.95
Latest analyst target
3. DCF / Fair value
$-11.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.95
Low
$9.50
High
$9.50
Mean
$9.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-09 | main | Ascendiant Capital | Buy → Buy | $10 |
| 2025-09-26 | main | Ascendiant Capital | Buy → Buy | $9 |
| 2025-07-28 | init | Ascendiant Capital | — → Buy | $9 |
- VA lung cancer trial tests new drug combo for patients with few options - Stock Titan Wed, 18 Feb 2026 13
- New Analyst Forecast: $ALLR Given $9.5 Price Target | ALLR Stock News - Quiver Quantitative ue, 09 Dec 2025 08
- Why Did Allarity Therapeutics Stock Double In Value Today? - MSN ue, 26 Aug 2025 07
- Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance Fri, 14 Nov 2025 08
- Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today? - TipRanks ue, 26 Aug 2025 07
- Allarity Therapeutics stock soars after FDA Fast Track designation - Investing.com ue, 26 Aug 2025 07
- Why Did Allarity Therapeutics Stock Double In Value Today? - Stocktwits ue, 26 Aug 2025 17
- Allarity Therapeutics Signs Common Stock Purchase Agreement With Tumim Stone Capital - TradingView hu, 29 Jan 2026 08
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga Wed, 11 Feb 2026 08
- FDA Fast-Tracks Promising Ovarian Cancer Drug: Allarity's Stenoparib Shows 22-Month Patient Benefits - Stock Titan ue, 26 Aug 2025 07
- Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships - Investing News Network Wed, 10 Sep 2025 23
- Allarity Therapeutics Raises Amidst Promising Developments - StocksToTrade ue, 26 Aug 2025 07
- Allarity Therapeutics Appoints Jeffrey Ervin as Full-Time CFO - TipRanks Mon, 08 Dec 2025 08
- Allarity Therapeutics Eyes New Horizons with Positive Updates - StocksToTrade Wed, 27 Aug 2025 07
- ALLR Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 133333 | — | — | Stock Award(Grant) at price 0.00 per share. | GRAFF JEREMY R. | President | — | 2026-01-07 00:00:00 | D |
| 1 | 39494 | nan | — | — | GRAFF JEREMY R. | President | — | 2025-09-30 00:00:00 | D |
| 2 | 396734 | — | — | Stock Award(Grant) at price 0.00 per share. | JENSEN THOMAS | Chief Executive Officer | — | 2025-01-22 00:00:00 | D |
| 3 | 144441 | — | — | Stock Award(Grant) at price 0.00 per share. | GRAFF JEREMY R. | Officer | — | 2025-01-22 00:00:00 | D |
| 4 | 29496 | — | — | Stock Award(Grant) at price 0.00 per share. | EPSHINSKY ALEXANDER | Chief Financial Officer | — | 2025-01-22 00:00:00 | D |
| 5 | 118483 | 249999.0 | — | Stock Award(Grant) at price 2.11 per share. | GRAFF JEREMY R. | President | — | 2024-09-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -110.77K | 1.34M | -42.74K | 675.54K |
| TaxRateForCalcs | 0.02 | 0.21 | 0.09 | 0.27 |
| NormalizedEBITDA | -17.00M | -17.66M | -16.80M | -28.27M |
| TotalUnusualItems | -7.24M | 6.38M | -494.00K | 2.50M |
| TotalUnusualItemsExcludingGoodwill | -7.24M | 6.38M | -494.00K | 2.50M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.52M | -11.90M | -16.06M | -26.65M |
| ReconciledDepreciation | 9.00K | 37.00K | 60.00K | 106.00K |
| EBITDA | -24.23M | -11.28M | -17.30M | -25.77M |
| EBIT | -24.24M | -11.32M | -17.36M | -25.88M |
| NetInterestIncome | -120.00K | -476.00K | -193.00K | -1.99M |
| InterestExpense | 653.00K | 498.00K | 223.00K | 640.00K |
| InterestIncome | 533.00K | 22.00K | 30.00K | 0.00 |
| NormalizedIncome | -17.39M | -16.94M | -15.61M | -28.47M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.52M | -11.90M | -16.06M | -26.65M |
| TotalExpenses | 17.54M | 17.13M | 16.89M | 26.56M |
| TotalOperatingIncomeAsReported | -27.24M | -17.13M | -34.46M | -26.56M |
| DilutedAverageShares | 1.61M | 3.38K | 662.00 | 337.00 |
| BasicAverageShares | 1.61M | 3.38K | 662.00 | 337.00 |
| DilutedEPS | -15.65 | -6.03K | -31.80K | -79.07K |
| BasicEPS | -15.65 | -6.03K | -31.80K | -79.07K |
| DilutedNIAvailtoComStockholders | -25.15M | -20.42M | -21.05M | -26.65M |
| NetIncomeCommonStockholders | -25.15M | -20.42M | -21.05M | -26.65M |
| PreferredStockDividends | 639.00K | 8.52M | 4.99M | |
| NetIncome | -24.52M | -11.90M | -16.06M | -26.65M |
| MinorityInterests | 0.00 | |||
| NetIncomeIncludingNoncontrollingInterests | -24.52M | -11.90M | -16.06M | -26.65M |
| NetIncomeContinuousOperations | -24.52M | -11.90M | -16.06M | -26.65M |
| TaxProvision | -381.00K | 83.00K | -1.52M | 133.00K |
| PretaxIncome | -24.90M | -11.82M | -17.58M | -26.52M |
| OtherIncomeExpense | -7.24M | 5.79M | -494.00K | 2.03M |
| OtherNonOperatingIncomeExpenses | -591.00K | -474.00K | ||
| SpecialIncomeCharges | -9.70M | 0.00 | -16.59M | 1.00M |
| GainOnSaleOfPPE | 0.00 | 1.78M | 1.00M | |
| OtherSpecialCharges | 800.00K | 141.00K | ||
| ImpairmentOfCapitalAssets | 9.70M | 0.00 | 17.57M | 0.00 |
| GainOnSaleOfSecurity | 2.46M | 6.38M | 16.10M | 1.50M |
| NetNonOperatingInterestIncomeExpense | -120.00K | -476.00K | -193.00K | -1.99M |
| TotalOtherFinanceCost | 1.35M | |||
| InterestExpenseNonOperating | 653.00K | 498.00K | 223.00K | 640.00K |
| InterestIncomeNonOperating | 533.00K | 22.00K | 30.00K | 0.00 |
| OperatingIncome | -17.54M | -17.13M | -16.89M | -26.56M |
| OperatingExpense | 17.54M | 17.13M | 16.89M | 26.56M |
| ResearchAndDevelopment | 6.10M | 7.10M | 6.93M | 14.20M |
| SellingGeneralAndAdministration | 11.44M | 10.03M | 9.96M | 12.36M |
| GeneralAndAdministrativeExpense | 11.44M | 10.03M | 9.96M | 12.36M |
| OtherGandA | 11.44M | 10.03M | 9.96M | 12.36M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 7.30M | 9.81K | 662.00 | 337.00 |
| ShareIssued | 7.30M | 9.81K | 662.00 | 337.00 |
| NetDebt | 1.13M | 1.70M | ||
| TotalDebt | 1.35M | 1.30M | 3.73M | 1.09M |
| TangibleBookValue | 11.81M | -14.36M | -9.66M | -9.98M |
| InvestedCapital | 13.16M | -3.19M | 3.61M | 19.13M |
| WorkingCapital | 11.50M | -12.20M | -6.25M | 685.00K |
| NetTangibleAssets | 11.81M | -12.62M | -7.66M | -9.35M |
| CapitalLeaseObligations | 0.00 | 8.00K | 107.00K | |
| CommonStockEquity | 11.81M | -4.49M | -113.00K | 18.15M |
| PreferredStockEquity | 1.74M | 2.00M | 632.00K | |
| TotalCapitalization | 11.81M | -2.75M | 2.97M | 19.76M |
| TotalEquityGrossMinorityInterest | 11.81M | -2.75M | 1.89M | 18.78M |
| StockholdersEquity | 11.81M | -2.75M | 1.89M | 18.78M |
| GainsLossesNotAffectingRetainedEarnings | -354.00K | -411.00K | -721.00K | -600.00K |
| OtherEquityAdjustments | -354.00K | -411.00K | -721.00K | -600.00K |
| RetainedEarnings | -118.97M | -94.45M | -82.55M | -66.49M |
| AdditionalPaidInCapital | 131.13M | 90.37M | 83.16M | 85.24M |
| CapitalStock | 1.00K | 1.74M | 2.00M | 633.00K |
| CommonStock | 1.00K | 0.00 | 0.00 | 1.00K |
| PreferredStock | 0.00 | 1.74M | 2.00M | 632.00K |
| TotalLiabilitiesNetMinorityInterest | 10.84M | 14.61M | 12.65M | 30.85M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 446.00K | 1.43M | 10.13M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 632.00K | |
| DerivativeProductLiabilities | 7.18M | |||
| NonCurrentDeferredLiabilities | 0.00 | 446.00K | 349.00K | 1.96M |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 446.00K | 349.00K | 1.96M |
| LongTermDebtAndCapitalLeaseObligation | 1.08M | 988.00K | ||
| LongTermCapitalLeaseObligation | 0.00 | 9.00K | ||
| LongTermDebt | 1.08M | 979.00K | ||
| CurrentLiabilities | 10.84M | 14.17M | 11.22M | 20.72M |
| OtherCurrentLiabilities | 1.00K | 3.08M | 374.00K | 11.27M |
| CurrentDebtAndCapitalLeaseObligation | 1.35M | 1.30M | 2.65M | 98.00K |
| CurrentCapitalLeaseObligation | 0.00 | 8.00K | 98.00K | |
| CurrentDebt | 1.35M | 1.30M | 2.64M | |
| OtherCurrentBorrowings | 1.35M | 1.30M | 2.64M | |
| LineOfCredit | 0.00 | |||
| CurrentNotesPayable | 0.00 | 2.64M | ||
| PayablesAndAccruedExpenses | 9.49M | 9.78M | 8.20M | 9.35M |
| CurrentAccruedExpenses | 5.23M | 1.31M | 1.90M | 8.59M |
| InterestPayable | 281.00K | 101.00K | 0.00 | |
| Payables | 4.26M | 8.47M | 6.29M | 758.00K |
| TotalTaxPayable | 74.00K | 59.00K | 41.00K | 60.00K |
| IncomeTaxPayable | 74.00K | 59.00K | 41.00K | 60.00K |
| AccountsPayable | 4.18M | 8.42M | 6.25M | 698.00K |
| TotalAssets | 22.65M | 11.86M | 14.54M | 49.63M |
| TotalNonCurrentAssets | 309.00K | 9.89M | 9.58M | 28.23M |
| InvestmentsAndAdvances | 350.00K | |||
| InvestmentinFinancialAssets | 350.00K | |||
| AvailableForSaleSecurities | 350.00K | |||
| GoodwillAndOtherIntangibleAssets | 0.00 | 9.87M | 9.55M | 28.14M |
| OtherIntangibleAssets | 9.87M | 9.55M | 28.14M | |
| NetPPE | 309.00K | 20.00K | 27.00K | 94.00K |
| AccumulatedDepreciation | -328.00K | |||
| GrossPPE | 309.00K | 20.00K | 27.00K | 94.00K |
| OtherProperties | 309.00K | 20.00K | 27.00K | 94.00K |
| CurrentAssets | 22.34M | 1.97M | 4.97M | 21.40M |
| CurrentDeferredAssets | 0.00 | 1.34M | 0.00 | |
| PrepaidAssets | 579.00K | 859.00K | 727.00K | 154.00K |
| Receivables | 2.23M | 946.00K | 871.00K | 1.34M |
| TaxesReceivable | 813.00K | 946.00K | 871.00K | 1.34M |
| AccountsReceivable | 1.42M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 19.53M | 166.00K | 2.03M | 19.91M |
| OtherShortTermInvestments | 0.00 | 350.00K | ||
| CashAndCashEquivalents | 19.53M | 166.00K | 2.03M | 19.55M |
| CashFinancial | 19.53M | 166.00K | 2.03M | 19.55M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -17.65M | -12.74M | -16.84M | -14.89M |
| RepurchaseOfCapitalStock | -3.50M | -6.65M | -1.51M | 0.00 |
| RepaymentOfDebt | -1.34M | -3.70M | 0.00 | -2.94M |
| IssuanceOfDebt | 1.34M | 1.05M | 1.00M | 4.00M |
| IssuanceOfCapitalStock | 40.29M | 18.05M | 0.00 | 32.12M |
| CapitalExpenditure | -298.00K | -18.00K | ||
| InterestPaidSupplementalData | 34.00K | 85.00K | 262.00K | |
| IncomeTaxPaidSupplementalData | 6.00K | 12.00K | 118.00K | |
| EndCashPosition | 19.53M | 166.00K | 2.03M | 19.55M |
| BeginningCashPosition | 166.00K | 2.03M | 19.55M | 298.00K |
| EffectOfExchangeRateChanges | 225.00K | -113.00K | -189.00K | -680.00K |
| ChangesInCash | 19.14M | -1.75M | -17.34M | 19.94M |
| FinancingCashFlow | 36.79M | 10.99M | -1.31M | 33.82M |
| CashFlowFromContinuingFinancingActivities | 36.79M | 10.99M | -1.31M | 33.82M |
| NetOtherFinancingCharges | -800.00K | -2.04M | ||
| ProceedsFromStockOptionExercised | 0.00 | 2.24M | 0.00 | 2.77M |
| NetPreferredStockIssuance | -562.00K | -5.49M | -1.51M | 0.00 |
| PreferredStockPayments | -3.50M | -6.65M | -1.51M | 0.00 |
| PreferredStockIssuance | 2.94M | 1.16M | 0.00 | |
| NetCommonStockIssuance | 37.35M | 16.89M | 0.00 | 32.12M |
| CommonStockIssuance | 37.35M | 16.89M | 0.00 | 32.12M |
| NetIssuancePaymentsOfDebt | 0.00 | -2.65M | 1.00M | 969.00K |
| NetShortTermDebtIssuance | 0.00 | -84.00K | ||
| NetLongTermDebtIssuance | 0.00 | -2.65M | 1.00M | 1.05M |
| LongTermDebtPayments | -1.34M | -3.70M | 0.00 | -2.94M |
| LongTermDebtIssuance | 1.34M | 1.05M | 1.00M | 4.00M |
| InvestingCashFlow | -298.00K | 0.00 | 791.00K | 1.00M |
| CashFlowFromContinuingInvestingActivities | -298.00K | 0.00 | 791.00K | 1.00M |
| NetIntangiblesPurchaseAndSale | 0.00 | 809.00K | 1.00M | |
| SaleOfIntangibles | 0.00 | 809.00K | 1.00M | |
| NetPPEPurchaseAndSale | -298.00K | 0.00 | -18.00K | 0.00 |
| PurchaseOfPPE | -298.00K | 0.00 | -18.00K | 0.00 |
| OperatingCashFlow | -17.35M | -12.74M | -16.82M | -14.89M |
| CashFlowFromContinuingOperatingActivities | -17.35M | -12.74M | -16.82M | -14.89M |
| ChangeInWorkingCapital | 63.00K | 3.35M | -328.00K | 5.57M |
| ChangeInOtherWorkingCapital | 207.00K | |||
| ChangeInOtherCurrentLiabilities | 0.00 | -8.00K | -99.00K | -124.00K |
| ChangeInOtherCurrentAssets | 94.00K | 1.35M | -1.08M | -330.00K |
| ChangeInPayablesAndAccruedExpense | -557.00K | 2.23M | 1.47M | 5.89M |
| ChangeInAccruedExpense | 3.54M | 43.00K | -4.72M | 7.20M |
| ChangeInPayable | -4.09M | 2.18M | 6.19M | -1.30M |
| ChangeInAccountPayable | -4.11M | 2.17M | 6.21M | -1.31M |
| ChangeInTaxPayable | 15.00K | 18.00K | -19.00K | 8.00K |
| ChangeInIncomeTaxPayable | 15.00K | 18.00K | -19.00K | 8.00K |
| ChangeInPrepaidAssets | 274.00K | -190.00K | -618.00K | 130.00K |
| ChangeInReceivables | 45.00K | -26.00K | 0.00 | 0.00 |
| ChangesInAccountReceivables | 0.00 | |||
| OtherNonCashItems | 566.00K | 1.57M | 138.00K | 2.06M |
| StockBasedCompensation | 71.00K | -71.00K | 1.75M | 6.37M |
| AssetImpairmentCharge | 9.70M | 0.00 | 17.57M | 0.00 |
| DeferredTax | -446.00K | 97.00K | -1.61M | 20.00K |
| DeferredIncomeTax | -446.00K | 97.00K | -1.61M | 20.00K |
| DepreciationAmortizationDepletion | 9.00K | 37.00K | 60.00K | 106.00K |
| DepreciationAndAmortization | 9.00K | 37.00K | 60.00K | 106.00K |
| OperatingGainsLosses | -2.80M | -5.83M | -18.34M | -2.36M |
| GainLossOnInvestmentSecurities | -2.68M | -5.65M | -17.01M | -1.59M |
| NetForeignCurrencyExchangeGainLoss | -126.00K | -179.00K | 450.00K | 95.00K |
| GainLossOnSaleOfPPE | 0.00 | -1.78M | -1.00M | |
| NetIncomeFromContinuingOperations | -24.52M | -11.90M | -16.06M | -26.65M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALLR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|